Datasheet is currently unavailable. Try again or CONTACT US
rHuman VEGF-165 Protein
009-001-B99
009-001-B99-0.1
10 µg
100 µg
Lyophilized
Lyophilized
SDS-PAGE
Human
E. coli
Shipping info:
$50.00 to US & $70.00 to Canada for most products. Final costs are calculated at checkout.
Product Details
VEGF-165 Human Recombinant Protein - 009-001-B99
Vascular endothelial growth factor A-165, VEGF-A165 cytokine, Vascular permeability factor, VPF-165
Human
E. coli
Recombinant Protein
Target Details
VEGFA - View All VEGFA Products
Purity was determined to be greater than 95% as determined by analysis by RP-HPLC and by reducing and non-reducing SDS-PAGE against known standard.
P15692 - UniProtKB
Application Details
SDS-PAGE
VEGF-165 Recombinant Protein has been tested by SDS-PAGE and is suitable as a control for polyclonal or monoclonal anti-VEGF-165 in immunological assays.
Formulation
0.1 mg/mL by UV absorbance at 280 nm
0.1% Trifluoroacetic acid
None
None
100 µL
Restore with deionized water (or equivalent)
Shipping & Handling
Ambient
Store vial at 4° C prior to restoration. Dilute only prior to immediate use. Maintain sterility. This product DOES NOT contain preservative. DO NOT VORTEX. We recommend adding a carrier protein such as HSA or BSA to 0.1% (i.e. 1.0 mg/mL) . For best results aliquot contents and freeze at -20° C or colder. Avoid cycles of freezing and thawing. Centrifuge vial before each opening to dislodge contents from the cap and to clarify if contents are not clear after standing at room temperature.
Expiration date is six (6) months from date of receipt.
Vascular endothelial growth factor-A was originally isolated from tumor cells and referred to as Tumor Angiogenesis Factor or Vascular Permeability Factor. Although expressed at high levels in certain tumor-derived cells it is produced by a wide variety of cell types. In addition to stimulating vascular growth and vascular permeability it may play a role in stimulating vasolidation via nitric oxide-dependent pathways. Alternative splicing of the mRNA for VEGF-A results in several isoforms of the protein being produced. Rat and bovine VEGF are one amino acid shorter than the human factor, and the bovine and human sequences show a homology of 95 percent.
In contrast to other factors mitogenic for endothelial cells such as FGF-1, FGF-2 and PDGF, VEGF is synthesized as a precursor containing a typical hydrophobic secretory signal sequence of 26 amino acids. Glycosylation is not required for efficient secretion of VEGF. Recombinant Human VEGF produced in E.coli is a double, non-glycosylated, polypeptide chain containing 165 amino acids and having a molecular mass of 38231 Daltons.
This product is for research use only and is not intended for therapeutic or diagnostic applications. Please contact a technical service representative for more information. All products of animal origin manufactured by Rockland Immunochemicals are derived from starting materials of North American origin. Collection was performed in United States Department of Agriculture (USDA) inspected facilities and all materials have been inspected and certified to be free of disease and suitable for exportation. All properties listed are typical characteristics and are not specifications. All suggestions and data are offered in good faith but without guarantee as conditions and methods of use of our products are beyond our control. All claims must be made within 30 days following the date of delivery. The prospective user must determine the suitability of our materials before adopting them on a commercial scale. Suggested uses of our products are not recommendations to use our products in violation of any patent or as a license under any patent of Rockland Immunochemicals, Inc. If you require a commercial license to use this material and do not have one, then return this material, unopened to: Rockland Inc., P.O. BOX 5199, Limerick, Pennsylvania, USA.
